Retatrutide: the strongest results in obesity medicine, and you cannot buy it. Here is the whole picture.
Retatrutide is Eli Lilly's next-generation weight-loss medicine, and the excitement is not hype: it works on three hormone pathways where tirzepatide works on two and semaglutide on one, and its phase 3 results are the strongest the field has produced. It is also an investigational drug. It is not FDA-approved, it is not available by prescription anywhere, and we do not sell it. This page exists because the internet is full of people who will sell you something with this name on the label, and you deserve the real status before you meet them.
The short answer
The results are real, the timeline is longer than the headlines imply, and nothing you can buy today is legitimate. Lilly has said it will file with the FDA in the first quarter of 2027, which puts approval, realistically, at late 2027 or beyond. Until then retatrutide exists only inside Lilly's trials and programs. If your goal is weight loss now rather than in two years, the closest prescribable relative is tirzepatide, the dual-pathway medicine, and whether it fits your case is exactly what a licensed clinician here reviews. That is the honest bridge, and it is the only one we will offer.
What it actually is
The GLP-1 class is an escalation of pathways. Semaglutide works on one incretin hormone. Tirzepatide added a second, GIP. Retatrutide adds a third, glucagon, which brings energy expenditure into the mechanism rather than appetite alone. That third pathway is why its trial numbers moved past everything before it, and why the field is paying attention. Mechanism is not destiny, and approval is not a formality, but this is not vaporware either: it is a serious medicine moving through the process at full speed.
The results everyone is quoting
In Lilly's lead phase 3 trial, participants at the highest doses averaged roughly a 30 percent reduction in body weight over two years, results the company compared to bariatric surgery territory. In the phase 3 cohorts with diabetes and cardiovascular disease, announced this July, average losses ran 21 to 23 percent, lower and still unprecedented for those harder populations. Two honest caveats belong next to every one of those numbers: they are averages from supervised trials, not individual promises, and they were produced by the trial product, which is not what any online seller is shipping.
When can you actually get it?
Lilly planned to file by the end of this year and has moved that to the first quarter of 2027, citing manufacturing and quality-control data. FDA review takes months after filing. Read together, that means no legitimate prescription retatrutide before late 2027 at the earliest, and that date is Lilly's to move, not ours. Anyone quoting you a nearer date is guessing, and anyone offering it to you today is the subject of the next section.
About the "retatrutide" already for sale online
There is a documented grey market selling powder under this name, labeled for research, priced to tempt, and answerable to nobody. Be clear about what that is. Retatrutide is an investigational medicine: there is no legitimate pharmacy pathway for it, no legitimate compounded version of it, and no telehealth platform that can lawfully prescribe it, including this one. A vial of it sold to a consumer today has no verified identity, purity, or dose, and no clinician behind it. We compound and prescribe real medicines through licensed US pharmacies, which is exactly why we will not touch this one until it exists as a real medicine. If a storefront will sell you retatrutide today, you have learned everything you need to know about that storefront.
What to do in the meantime
If the headline that brought you here was the weight loss, the working version of that medicine class already exists. Tirzepatide carries two of retatrutide's three pathways and is prescribable today, after review by a licensed clinician; semaglutide remains the established single-pathway option. Which fits you, or whether neither does, is a clinical decision, and we wrote the comparison plainly rather than as a sales page. Waiting for retatrutide is also a legitimate choice, and a clinician can tell you honestly what waiting two years means for your specific picture.
Questions
What happens if I am not approved?
You are not charged. Your clinician explains the reasoning and, where useful, what a better next step may be. Reviews are typically completed in under 24 hours.
Is retatrutide available anywhere at all right now?
Only inside Eli Lilly's clinical trials and access programs, on Lilly's terms. Nothing sold to consumers today is a legitimate version of this medicine.
Can compounding pharmacies make retatrutide?
No. It is an investigational drug without FDA approval, and there is no legitimate compounding pathway for it. Products labeled "compounded retatrutide" are operating outside the system that makes compounding legitimate, and that distinction is the entire reason our own compounded medicines mean something.
Will AnthologyRX carry retatrutide when it is approved?
We are watching it as closely as anyone in this field. What we offer, and when, will follow the same rule as everything in the catalogue: legitimate sourcing, licensed pharmacies, clinician review, or we do not offer it. No promises ahead of the facts.
Is retatrutide better than tirzepatide?
Its trial averages are stronger, and averages are where the honest comparison ends today, because one of these medicines has an approval, years of real-world use, and a supply chain, and the other does not yet exist outside trials. Ask the question again in 2027.
Ready when you are.
About 10 minutes. No charge unless your clinician approves.